- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] INCIDENTAL FINDING OF LOW SERUM IGA IN TYPE 1 DIABETES MELLITUS REVEALS DIAGNOSIS OF CVID () - Nov 21, 2020 - Abstract #ACAAI2020ACAAI_688;
He displayed insufficient protection to polysaccharide vaccine and did not respond to Pneumovax 23 booster...No known genetic link has been found. It is important to take a detailed history for recurrent infections in patients with history of autoimmune disease, as a diagnosis of primary immunodeficiency may be revealed.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] PNEUMOCOCCAL DEBACLE – REACTION TO A COMMON VACCINE () - Nov 21, 2020 - Abstract #ACAAI2020ACAAI_641;
In the US, the PPSV-23 vaccine is indicated for adults older than 65 and those with underlying conditions that put them at increased risk for pneumococcal disease...This case demonstrates how a patient may present and one management strategy. Ultimately, unnecessary antibiotic treatment was avoided in a patient for whom there was a high clinical suspicion of a vaccine reaction.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Optimising immunisation in children with 22q11 microdeletion. (Pubmed Central) - Nov 6, 2020
Of the total sample of children, 18% received a fourth dose of conjugate pneumococcal vaccine (Prevenar 7 or 13) and 16% received a dose of Pneumovax 23 from 4 years of age...Most patients' immune profiles were consistent with mild-to-moderate immunodeficiency. We propose an immunological investigation and vaccination pathway with the aim of providing guidance and consistency to clinicians caring for children with 22q11 microdeletion.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Vaccination Response after Autologous Stem Cell Transplantation (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4122;
The current ASCT protocol for active immunization includes three doses of pneumococcal conjugate vaccine (PCV13) from 6-12 months after ASCT, followed by a 23-valent polysaccharide pneumococcal vaccine (PPSV23)...Further studies may need to explore pathophysiology of vaccine failure. Strategies to enhance immune reconstitution may augment the immune response and improve the outcome of the patients with ASCT.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
[VIRTUAL] Integrated Primary Specialty Care Access for Adults with Sickle Cell Disease in Delaware (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2949;
Therapeutic counseling, support groups and preventive health maintenance services were measured by: outpatient visits to the clinic, access to disease modifying therapies (hydroxyurea therapy or chronic transfusion therapy), immunizations (Pneumococcal), Depression Screens and Personalized Sickle Care Plans (Table)...48% of the patients received a pneumococcal vaccine (Pneumovax 23 val - n=16/33 and Prevnar 13 - n=7/33) and three (n=3/33) received both Pneumococcal vaccines...Unique challenges in managing adult SCD acute and chronic pain were addressed. Overall, this is one model for access to integrated primary specialty care and behavioral health services for persons with SCD across their lifespan.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: An Analysis of Adherence to Vaccination Recommendations in a Thoracic Organ Transplant Cohort. (Pubmed Central) - Oct 30, 2020
We assessed demographics, causes of organ failure, pretransplant hepatitis B immune status, and completion rates for hepatitis B vaccine series, pneumococcal conjugate vaccine (PCV13), and pneumococcal polysaccharide vaccine (PPSV23)...There was only a 47.3% and 72.3% completion rate overall in the post-transplant setting. (4) There continues to be a need for a comprehensive and coordinated effort to increase vaccine adherence for all SOT candidates in the pretransplant setting.
- |||||||||| SP0202 / Sanofi, SK Bio
Enrollment open: Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years. (clinicaltrials.gov) - Oct 19, 2020
P2, N=750, Recruiting,
(4) There continues to be a need for a comprehensive and coordinated effort to increase vaccine adherence for all SOT candidates in the pretransplant setting. Not yet recruiting --> Recruiting
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] RACIAL DISPARITIES IN PPSV-23 VACCINE ADMINISTRATION IN SMOKERS () - Oct 12, 2020 - Abstract #CHEST2020CHEST_1826;
Furthermore, there is a racial disparity for those who are offered the vaccine with blacks offered more frequently than whites, hispanics, other/unknown, and asians combined. There may also be a disparity in blacks versus whites however our sample size for these patients was too small to find statistical significance.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE-INDUCED GUILLIAN-BARRÉ SYNDROME () - Oct 12, 2020 - Abstract #CHEST2020CHEST_789;
Carefully administering PCV13 when truly indicated can further minimize the potential for harm. The development of injection site reactions should be carefully monitored as higher IgG-specific antibody titers could increase risk of GBS.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Pneumococcal carriage among adults aged 50 years and older with co-morbidities attending medical practices in Rome, Italy. (Pubmed Central) - Oct 11, 2020
A high prevalence of S. pneumoniae carriage was observed among adults with co-morbidities, especially among individuals affected by chronic lung diseases. These results support vaccine strategies based on the sequential administration of PCV13 and PPV23 to control potentially invasive pneumococcal strains in adults, especially in subjects with co-morbidities.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Rethinking results from the Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial. (Pubmed Central) - Oct 11, 2020
We argue that serious issues with internal and external validity exist that affect the usefulness of these data when evaluating pneumococcal vaccines for the general adult population. As one example of internal data inconsistency, the values reported for the percent of all pneumonia cases due to pneumococcus and the vaccine efficacy (VE) for all cause pneumonia are mutually inconsistent, even based on unrealistically high values for PPSV23 VE against vaccine serotypes and the proportion of pneumococcal pneumonias due to vaccine serotypes.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events. (Pubmed Central) - Oct 10, 2020
As one example of internal data inconsistency, the values reported for the percent of all pneumonia cases due to pneumococcus and the vaccine efficacy (VE) for all cause pneumonia are mutually inconsistent, even based on unrealistically high values for PPSV23 VE against vaccine serotypes and the proportion of pneumococcal pneumonias due to vaccine serotypes. The PPSV23 vaccination is associated with a good prognosis and a low-risk of cardiac events in dialysis patients; however, there was no evidence indicating enhanced protective efficacy against pneumonia, suggesting the PPSV23 vaccination might improve the prognosis by directly preventing cardiovascular events.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Improving Pneumococcal Vaccination in Veterans with Rheumatic Diseases () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2321;
The lack of statistically significant change in our primary outcome measure is likely explained by our sampling strategy, which samples from all providers’ clinics, though the intervention had only been rolled out in about half of the providers’ clinics before the COVID-19 pandemic. A more upstream process measure is the number of pneumococcal vaccinations administered in clinic each month, where we have seen signs of improvement.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Increasing the Rate of Pneumococcal Vaccination in an Academic Rheumatology Outpatient Clinic () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1215;
This quality improvement project utilizes the medical record to remind providers to discuss appropriate pneumococcal vaccination based on an algorithm and rapidly order the vaccine if the patient agrees. We have shown in our clinic that BPAs are effective at increasing pneumococcal vaccination rates in our outpatient rheumatology clinic.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients (Feed 9) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_1030;
Using quality improvement methodology, pneumococcal vaccination rates significantly increased and have been sustained in our immunosuppressed pediatric rheumatology patients. We continue to prioritize this important initiative through a multi-specialty project and through pre-visit planning by identifying additional rheumatology patients on immunosuppression that are eligible for pneumococcal vaccination.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Fluarix (influenza virus trivalent vaccine) / GSK, NN1213 / Novo Nordisk
Enrollment closed: Perturbing of HIV Reservoir With Immune Stimulation (clinicaltrials.gov) - Oct 7, 2020
P=N/A, N=56, Active, not recruiting,
We have found that 10-15% of families are against vaccinations, so a goal of 100% vaccinations is not achievable. Recruiting --> Active, not recruiting
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Preclinical, Journal: Re-validation and update of an extended-specificity multiplex assay for detection of Streptococcus pneumoniae capsular serotype/serogroup-specific antigen and cell-wall polysaccharide in urine specimens. (Pubmed Central) - Sep 27, 2020
The assay uses human mAbs that detect the 24 pneumococcal serotype/groups targeted by the pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccine (PPV-23) plus some cross-reactive types and the pneumococcal cell-wall polysaccharide...Here we report on the further development and re-validation of a new version of the assay (version 2.1), which offers improved sensitivity towards serotypes 7F, 18C and 19F and increased specificity for serotypes 7F, 20 and 22F by replacement of some of the antibody clones with new clones. Using a panel of urine specimens from patients diagnosed with community-acquired pneumonia or pneumococcal disease, the overall clinical sensitivity of this version of the assay based on isolation of S. pneumoniae from a normally sterile site is 94.3 % and the clinical specificity is 93.6 %, in comparison with clinical sensitivity and specificity values of 96.2 % and 89.9 % in the previous assay.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Efficacy evaluation after 5 years of inoculation of 23 valent pneumococcal polysaccharide vaccine for the elderly aged 60 years old and above in Shanghai during 2013-2018 (Pubmed Central) - Sep 26, 2020
After adjusting for age, RR (95%CI) was 0.699 (0.507-0.956), and the difference was still statistically significant (P=0.025).Further stratified analysis showed that the vaccine protective rates of PPV23 in the 60-69 year-old group, the 70-79 year-old group and the ≥80 year-old group were 36.7%, 21.6% and 26.0%, respectively, but only in the 60-69 year-old group showed statistical difference (RR=0.633, 95%CI=0.399-0.990, P=0.045). To a certain extent, the incidence of CAP can be reduced by inoculation of PPV23 in elderly population aged 60 and above in Shanghai, and it should be further recommended in elderly population of low age.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Analysis on the project personnel's attitude and its influential factors of 23-valent pneumococcal polysaccharide vaccination program for the elderly in Shanghai (Pubmed Central) - Sep 26, 2020
For the program's conversion to routine vaccination, people under 35 years old, in Qingpu District, in the vaccination clinic, and those believing that the project was not scientific and difficult to implement had low support rate, and the OR (95%CI) were 0.56 (0.32-0.98), 0.48 (0.26-0.89), 0.26 (0.12-0.59), 0.58 (0.42-0.79) and 0.50 (0.30-0.81); people with technical secondary school or senior school, in Jiading, Putuo or Minhang District, believing that PPV23 was effective in the prevention of pneumococcal pneumonia in the elderly, and those who were willing to vaccinate the elderly with PPV23 had higher support rate, and the OR (95%CI) were 1.63 (1.11-2.39), 2.28 (1.71-3.03), 1.69 (1.25-2.28) and 4.10 (2.86-5.88). The support rate of pneumococcal vaccination project for the elderly in Shanghai needs to be improved, especially its conversion to the routine vaccination.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Review, Journal: Effectiveness of 23-valent pneumococcal polysaccharide vaccine on adult pneumococcal disease (Pubmed Central) - Sep 26, 2020
Here, we review the prevalence of adult pneumococcal diseases, the preventive and protective effects and benefits of PPV23 vaccine on high-risk population, especially the elderly individuals. We hope this review can provide references and new ideas for adult PPV23 vaccination programs in China.
- |||||||||| pneumococcal conjugate vaccine (V114) / Merck (MSD)
[VIRTUAL] Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults infected with HIV: a phase III trial () - Sep 21, 2020 - Abstract #HIVGlasgow2020HIV-Glasgow_156;
We hope this review can provide references and new ideas for adult PPV23 vaccination programs in China. In pneumococcal vaccine‐naïve adults infected with HIV, V114 followed eight weeks later by PPSV23, as per recommendations aimed at prevention of PD in HIV‐infected individuals, is generally well tolerated, and induces immune responses for all 15 pneumococcal serotypes as assessed by OPA geometric mean titers and IgG geometric mean concentrations at 30 days after V114 and after PPSV23 administration.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Improving Vaccination Rates in Patients With Inflammatory Bowel Disease () - Sep 15, 2020 - Abstract #ACG2020ACG_3157;
The percentage of missed opportunities in the baseline data for influenza, PCV13/PPSV23, HBV, TDAP, and Zoster were 80%, 60%, 71.43%, 17.14%, 100%, respectively. This decreased to 22%, 22.22%, 22.22%, 16.67%, and 37.50% respectively by March 2020.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Impact of Type of GI Provider on Vaccination Rates Among Inflammatory Bowel Disease Patients () - Sep 15, 2020 - Abstract #ACG2020ACG_2261;
HBV was the only vaccine where there was a significant difference in vaccination rate by type of GI provider (Table 2). Multivariate analysis showed that patients who followed up with IBD specialists and GI fellows were more likely to be vaccinated for HBV than patients who followed up with general GI providers (OR = 2.55, p = .003 and OR = 2.73, p = .007 respectively [Table 3]).
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Clinical Experience of the Machine Learning-Based Automated Treatment Planning Tool for Breast Radiotherapy (Poster Hall) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_754;
Clinical experience with MLAP reveals that auto-plans are equivalent to the final-plans in target coverage, but improvement is to be made to reduce high dose volume for cases with nodal irradiation. This study demonstrates the feasibility auto planning and significance of integrating human experience and feedback to improve MLAP for better clinical translation.
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: Treatment and Prevention of Pneumococcal Infection. (Pubmed Central) - Sep 9, 2020
The most appropriate antibiotics for treatment pneumococcal infection are macrolides, beta-lactams, and quinolones. Two vaccines, PPSV23 and PCV13, are highly effective in preventing infection.
|
